ANNX at a glance
The past year
Chart−23.6% $3.10, close Nov 20
- From the highest close
- −55.5%
- Vs the 200-day average
- −38.4%
Short interest
History29.0M shares
- Of shares outstanding
- 15.2%
- Since the last report
- −8.4%
- Days to cover
- 7.2 days
- Settled
- Oct 30, 2026
Insider buying, 7 days
Filings$121,720 bought on the open market
- Purchases
- 1
- Form 4s filed
- Nov 15 – Nov 21
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
ANNX price history
Loading recent earnings…
Investment thesis
What must happen next
Annexon's platform must show that targeted complement/C1q inhibition produces differentiated clinical benefit or safety versus broader complement and immunology alternatives; without that, the company has little durable pricing power or partner leverage.HoldingMateriality: High
GAAP annual operating loss was $216.4 million in FY2025, showing substantial ongoing investment in development capacity. If the biology is validated, losses are investment in a scarce drug asset; if not, operating spend is value-destructive burn.
Watch: A lead program fails a pivotal or registrational trial endpoint or shows a safety signal that undermines chronic or acute use.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating loss was $216.4 million in FY2025, showing substantial ongoing investment in development capacity.
Open source ↗Annexon's clinical optionality depends on its cash lasting until value-creating data or regulatory milestones, because a forced financing before de-risking would shift upside from existing holders to new capital.HoldingMateriality: High
Cash was $162.1 million at December 31, 2025, up from $49.5 million at December 31, 2024. Adequate runway lets shareholders own the catalyst; insufficient runway turns even good science into a dilution problem.
Watch: A regulator asks for additional studies or longer follow-up, extending the time and cost to the next approval-relevant milestone.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Cash was $162.1 million at December 31, 2025, up from $49.5 million at December 31, 2024.
Open source ↗Management must convert rising cash burn into nearer-term registrational or regulatory de-risking rather than open-ended platform expansion; otherwise scale works against shareholders.WeakeningMateriality: Medium
GAAP annual operating cash flow was negative $186.4 million in FY2025, compared with negative $118.0 million in FY2024. The owner benefits only if each incremental dollar of burn increases approval probability or asset value; unfocused spend shortens runway without improving odds.
Watch: The company starts multiple large trials before a lead program has produced decisive de-risking data.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating cash flow was negative $186.4 million in FY2025, compared with negative $118.0 million in FY2024.
Open source ↗Annexon's small specialist operating model must remain an advantage by outsourcing or partnering capital-intensive functions until approval is closer; a premature commercial or manufacturing buildout would reduce financial flexibility.HoldingMateriality: Medium
The profile reports 96 employees, indicating a relatively small organization for a public drug developer. A lean model preserves option value in a binary biotech; a fixed-cost buildout raises the break-even hurdle before the product risk is resolved.
Watch: The company begins a large commercial hiring campaign before approval probability and launch timing are substantially de-risked.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
The profile reports 96 employees, indicating a relatively small organization for a public drug developer.
Open source ↗Low balance-sheet leverage preserves strategic optionality while the pipeline is still binary; restrictive debt, royalty, or liability growth would transfer part of the upside away from common shareholders.StrengtheningMateriality: Medium
Liabilities were $65.9 million at December 31, 2025, compared with assets of $277.6 million. If positive data arrive, a clean balance sheet lets equity holders capture more of the re-rating; if obligations rise, the upside is shared with creditors or royalty holders.
Watch: The company raises capital through restrictive debt or royalty financing tied to future product economics.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Liabilities were $65.9 million at December 31, 2025, compared with assets of $277.6 million.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Annexon's platform must show that targeted complement/C1q inhibition produces differentiated clinical benefit or safety versus broader complement and immunology alternatives; without that, the company has little durable pricing power or partner leverage. If the biology is validated, losses are investment in a scarce drug asset; if not, operating spend is value-destructive burn.
Annexon's clinical optionality depends on its cash lasting until value-creating data or regulatory milestones, because a forced financing before de-risking would shift upside from existing holders to new capital. Adequate runway lets shareholders own the catalyst; insufficient runway turns even good science into a dilution problem.
Management must convert rising cash burn into nearer-term registrational or regulatory de-risking rather than open-ended platform expansion; otherwise scale works against shareholders. The owner benefits only if each incremental dollar of burn increases approval probability or asset value; unfocused spend shortens runway without improving odds.
Annexon's small specialist operating model must remain an advantage by outsourcing or partnering capital-intensive functions until approval is closer; a premature commercial or manufacturing buildout would reduce financial flexibility. A lean model preserves option value in a binary biotech; a fixed-cost buildout raises the break-even hurdle before the product risk is resolved.
Low balance-sheet leverage preserves strategic optionality while the pipeline is still binary; restrictive debt, royalty, or liability growth would transfer part of the upside away from common shareholders. If positive data arrive, a clean balance sheet lets equity holders capture more of the re-rating; if obligations rise, the upside is shared with creditors or royalty holders.
All standing thesis claims
Original report summary
its complement/C1q pipeline produces de-risking clinical or regulatory events before financing needs dilute away the upside.
Bull case and bear case
Bull case and bear case for Annexon
Where the evidence on Annexon disagrees: Mixed on the latest evidence (Oct 15, 2026). Of its 5 thesis points, 1 strengthening, 3 holding and 1 weakening.
Bull case: what the evidence supports
Annexon's platform must show that targeted complement/C1q inhibition produces differentiated clinical benefit or safety versus broader complement and immunology alternatives; without that, the company has little durable pricing power or partner leverage.
Annexon's clinical optionality depends on its cash lasting until value-creating data or regulatory milestones, because a forced financing before de-risking would shift upside from existing holders to new capital.
Annexon's small specialist operating model must remain an advantage by outsourcing or partnering capital-intensive functions until approval is closer; a premature commercial or manufacturing buildout would reduce financial flexibility.
Low balance-sheet leverage preserves strategic optionality while the pipeline is still binary; restrictive debt, royalty, or liability growth would transfer part of the upside away from common shareholders.
Bear case: what the evidence questions
Management must convert rising cash burn into nearer-term registrational or regulatory de-risking rather than open-ended platform expansion; otherwise scale works against shareholders.
Thesis-Break Engine
Thesis-break watch · Annexon
No break has crossed Annexon’s thesis. Its break conditions are checked against every new filing as it lands.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedReported results of operations (earnings release).
Annexon filed an SEC 8-K on 2026-08-12: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
- MixedDirector or principal officer change.
Annexon filed an SEC 8-K on 2026-08-10: Director or principal officer change. It is a dated development that tests the current thesis.
- MixedOther material event.
Annexon filed an SEC 8-K on 2026-08-06: Other material event. It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- A lead program fails a pivotal or registrational trial endpoint or shows a safety signal that undermines chronic or acute use.
- A regulator asks for additional studies or longer follow-up, extending the time and cost to the next approval-relevant milestone.
- The company starts multiple large trials before a lead program has produced decisive de-risking data.
- The company begins a large commercial hiring campaign before approval probability and launch timing are substantially de-risked.
- The company raises capital through restrictive debt or royalty financing tied to future product economics.
ANNX news
Loading headlines…
Financial statements
ANNX income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
ANNX: quick answers
- When does Annexon (ANNX) report earnings next?
- Annexon's next results are projected for February 8, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 9, 2026. Earnings calendar
- What is ANNX's short interest?
- As of October 30, 2026, 29.0M ANNX shares were sold short, 15.2% of its shares outstanding, down 8.4% from the count before. At the stock's average daily volume that is 7.2 days to cover. FINRA publishes the count twice a month. ANNX short interest history

